David Millrine is a translational immunologist and biomarker scientist and Cancer Research UK National Biomarker Centre, where he leads a cross-functional team of researchers developing precision medicine strategies for cancer immunotherapy.

His scientific training spanned nearly a decade in Japan – including a PhD and postdoctoral fellowship at the WPI immunology Frontier Research Centre, Osaka University, under Tadamitsu Kashimoto (discoverer of IL-6 and tocilizumab) – where he investigated the mechanism of action of thalidomide-class immunomodulatory drugs. Subsequent postdoctoral positions at Cardiff University and the MRC Protein Phosphorylation and Ubiquitylation Unit, Dundee, broadened his expertise across cytokine signalling and the ubiquitin system, where he contributed to breakthrough studies published in Nature, J.Immunol., Nature Immunology, EMBO Journal, and Cell Reports.

At Manchester, his team profiles the peripheral and tumour immune microenvironment to understand the biology of immunotherapy response, with a particular focus on T-cell engagers in multiple myeloma and the evaluation of novel therapeutic targets. Alongside this, he has developed a research interest in the immunobiology of small cell lung cancer, including co-leading a study revealing an unrecognised post-transcriptional block to antigen presentation with implications for immunotherapy combination strategies.